ArticleAnnals of neurology2018

Permeability of the blood-brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis.

Stig P Cramer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.